PatientFinder is an online, user-driven, flexible data set that you can easily manipulate to reveal the true disease opportunity at a local level. This is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated.

Questions answered include:

• Which states and MSAs have the greatest number of patients with insurance?

• How many patients have the disease but are not treated in each territory?

• How many insured patients would be gained in each local market if territories with poor treatment rates were brought up to the national average?

PatientFinder provides:

• Disease-specific prevalence numbers for each U.S. state and MSA

• Examination of treatment rates for the disease population to create % treated and % untreated estimates by state and MSA

• Unique analysis of the untreated population examined through a filter of Rx benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory—the true local measure of opportunity for pharma companies

PatientFinder is the first burden of disease data set that reveals true market expansion opportunity at a local level. It will provide the following information for each of the 50 states and 318 MSAs:

Demographics

• Population breakdown by age, gender,race, and socioeconomic status

• Insured Population

• Uninsured as % of population

• Insured with Rx benefit

Disease Insight

• Prevalence of disease

• Prevalence as % of population

• Treated for disease

• Treated as % of population

• Untreated for disease 

• Untreated as % of population

• Untreated with Rx benefit

With this information, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase DTC, work with the local managed care organization to increase awareness of the disease and benefits of their drug, or align reps to maximize market potential.